Adaptive Biotechnologies (ADPT) Assets Average (2019 - 2026)

Adaptive Biotechnologies has disclosed Assets Average across 8 years of filings, most recently posting $509.3 million for Q1 2026.

• Assets Average for Q1 2026 came in at $509.3 million, down 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $509.3 million (down 3.0% YoY), and the FY2025 annual result was $526.1 million, down 12.36% from the prior year.
• Assets Average came in at $509.3 million for Q1 2026 at Adaptive Biotechnologies, up from $501.7 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $890.8 million in Q1 2022 to a low of $493.6 million in Q3 2025.
• The 5-year median for Assets Average is $640.7 million (2024), against an average of $668.8 million.
• Across the five-year window, Assets Average declined 22.86% in 2024 and decreased 3.0% in 2026, its largest moves.
• Adaptive Biotechnologies' Assets Average stood at $870.4 million in 2022, then slipped by 20.8% to $689.4 million in 2023, then decreased by 20.38% to $548.9 million in 2024, then declined by 8.61% to $501.7 million in 2025, then climbed by 1.53% to $509.3 million in 2026.
• The last three Assets Average figures came in at $509.3 million (Q1 2026), $501.7 million (Q4 2025), and $493.6 million (Q3 2025), per Business Quant data.